193 related articles for article (PubMed ID: 24958831)
1. Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.
Grunwald MR; Spivak JL
J Clin Oncol; 2016 Feb; 34(5):e38-40. PubMed ID: 24958831
[No Abstract] [Full Text] [Related]
2. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
3. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis.
Samuelson BT; Vesely SK; Chai-Adisaksopha C; Scott BL; Crowther M; Garcia D
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):648-52. PubMed ID: 26569516
[TBL] [Abstract][Full Text] [Related]
4. Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.
Helbig G; Wichary R; Torba K; Kyrcz-Krzemień S
Med Oncol; 2017 Mar; 34(3):31. PubMed ID: 28120162
[No Abstract] [Full Text] [Related]
5. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.
Masarova L; Mesa RA; Hernández-Boluda JC; Taylor JA
Leuk Res; 2020 Apr; 91():106338. PubMed ID: 32200188
[No Abstract] [Full Text] [Related]
6. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
8. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
9. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.
Gisslinger H; Schalling M; Gisslinger B; Skrabs C; Müllauer L; Kralovics R
Am J Hematol; 2014 Mar; 89(3):344-6. PubMed ID: 24273107
[No Abstract] [Full Text] [Related]
10. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
Bjørn ME; Holmström MO; Hasselbalch HC
Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
[TBL] [Abstract][Full Text] [Related]
15. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
16. [Hematologic Malignancies/Pediatric Malignancies. I. Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera].
Komatsu N
Gan To Kagaku Ryoho; 2016 May; 43(5):530-4. PubMed ID: 27344680
[No Abstract] [Full Text] [Related]
17. Infections associated with ruxolitinib: study in the French Pharmacovigilance database.
Sylvine P; Thomas S; Pirayeh E;
Ann Hematol; 2018 May; 97(5):913-914. PubMed ID: 29340760
[No Abstract] [Full Text] [Related]
18. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.
Slot S; Raymakers RAP; Schaap N; Span LFR; Koene HR; Kersting S; Te Boekhorst PAW; Westerman M; Schouten HC; Zweegman S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):624-634. PubMed ID: 31427260
[TBL] [Abstract][Full Text] [Related]
20. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
